Zura Bio (NASDAQ:ZURA) Announces Earnings Results, Misses Expectations By $0.02 EPS

Zura Bio (NASDAQ:ZURA) posted its quarterly earnings data on Thursday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02), Zacks reports.

Zura Bio Price Performance

Shares of ZURA stock traded down $0.41 during mid-day trading on Thursday, hitting $4.22. 326,542 shares of the stock traded hands, compared to its average volume of 846,515. Zura Bio has a 52-week low of $0.97 and a 52-week high of $4.68. The stock has a market cap of $274.38 million, a P/E ratio of -6.13 and a beta of 0.24. The stock’s fifty day moving average is $3.22 and its two-hundred day moving average is $2.03.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of Zura Bio from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research note on Tuesday, October 14th. Oppenheimer decreased their target price on Zura Bio from $17.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, August 15th. HC Wainwright lowered their target price on Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 19th. Finally, Chardan Capital restated a “buy” rating and set a $10.00 price target on shares of Zura Bio in a research note on Tuesday, September 30th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Zura Bio has an average rating of “Moderate Buy” and a consensus target price of $10.75.

Hedge Funds Weigh In On Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of ZURA. AQR Capital Management LLC purchased a new position in Zura Bio during the 1st quarter worth approximately $72,000. Bank of America Corp DE increased its stake in shares of Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after acquiring an additional 9,966 shares during the period. Jane Street Group LLC purchased a new position in shares of Zura Bio during the second quarter worth $113,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Zura Bio by 78.7% during the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after purchasing an additional 2,052,732 shares during the last quarter. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.